Sea buckthorn flavonoids and their derivatives: potential natural compounds for the treatment of diabetic cardiomyopathy
- PMID: 40746722
- PMCID: PMC12310634
- DOI: 10.3389/fphar.2025.1599756
Sea buckthorn flavonoids and their derivatives: potential natural compounds for the treatment of diabetic cardiomyopathy
Abstract
Diabetic cardiomyopathy (DCM) is one of the most common complications of diabetes, characterized by high morbidity and disability rates, and can lead to heart failure. However, specific therapeutic agents for DCM are currently lacking. Natural compounds derived from traditional Chinese medicine have demonstrated potential in alleviating DCM through multiple mechanisms. Sea buckthorn flavonoids and their derivatives represent a promising class of natural compounds for the treatment of DCM. These compounds have been shown to improve DCM by combating oxidative stress, inhibiting inflammatory responses, regulating epigenetic modifications, modulating autophagy and apoptosis, maintaining mitochondrial homeostasis, alleviating endoplasmic reticulum stress, reducing advanced glycation end products (AGEs) level, and ameliorating cardiomyocyte hypertrophy and myocardial fibrosis. This article provides a brief overview of the pharmacological effects of sea buckthorn flavonoids and their derivatives and systematically reviews their mechanisms in improving DCM. The aim is to promote the effective utilization of herbal medicine and provide insights and references for the development of novel therapeutics for DCM.
Keywords: diabetic cardiomyopathy; flavonoids; molecular mechanisms; natural compounds; sea buckthorn.
Copyright © 2025 Zhang, Zhang, Ouyang, Liu, Xie and Fu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Alshehri A. S., El-Kott A. F., Eleawa S. M., El-Gerbed M. S. A., Khalifa H. S., El-Kenawy A. E., et al. (2021). Kaempferol protects against streptozotocin-induced diabetic cardiomyopathy in rats by a hypoglycemic effect and upregulating SIRT1. J. Physiology Pharmacol. 72 (3). 10.26402/jpp.2021.3.04 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
